Skip to content

Evolutionary Genomics, Inc.: 10-K filed 2022-03-22

What Evolutionary Genomics, Inc. reported in its annual report filed 2022-03-22 (fiscal FY 2021): 33 published measures, 75 facts as tagged in accession 0001553350-22-000231.

This filing

Form
10-K (annual report)
Filed
2022-03-22
Fiscal period
fiscal FY 2021
Accession
0001553350-22-000231 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Evolutionary Genomics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-12-312,932,091USD
At 2020-12-313,992,699USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2021-12-313,762,613USD
At 2020-12-312,248,995USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-12-31-4,400,116USD
At 2021-09-30-3,787,201USD
At 2021-06-30-2,783,474USD
At 2021-03-31-2,284,702USD
At 2020-12-31-1,825,890USD
At 2020-09-30-169,665USD
At 2020-06-30-760,480USD
At 2020-03-31-520,611USD
At 2019-12-31-333,725USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2021-12-31214,009USD
At 2020-12-31215,836USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2021-01-01 to 2021-12-31-2,793,944USD365
2020-01-01 to 2020-12-31-1,711,883USD366

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2021-01-01 to 2021-12-31-1,583,138USD365
2020-01-01 to 2020-12-31-2,297,317USD366

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2020-01-01 to 2020-12-3112,500USD366

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2021-01-01 to 2021-12-311,581,311USD365
2020-01-01 to 2020-12-312,320,099USD366

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-12-31147,613USD366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-12-31-17,877,496USD
At 2020-12-31-15,083,552USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-987,353USD366

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2021-12-3118,698USD
At 2020-12-3150,763USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2021-01-01 to 2021-12-31219,718USD365
2020-01-01 to 2020-12-31219,718USD366

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-12-31-2,877,943USD365
2020-01-01 to 2020-12-31-2,879,795USD366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-12-31255,801USD
At 2020-12-31277,593USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2021-12-3118,866USD
At 2020-12-313,164USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2021-12-312,657,592USD
At 2020-12-313,664,343USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2021-01-01 to 2021-12-312,877,943USD365
2020-01-01 to 2020-12-312,892,295USD366

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2021-01-01 to 2021-12-311,234,215USD365
2020-01-01 to 2020-12-311,793,145USD366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-12-315,881,898shares
At 2020-12-315,881,898shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2021-12-31214,009USD
At 2020-12-31215,836USD
At 2019-12-3145,441USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2021-12-31503,665USD
At 2020-12-31503,665USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2021-12-31484,967USD
At 2020-12-31452,902USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2021-12-31652,145USD
At 2020-12-31903,283USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2021-01-01 to 2021-12-31-2,793,944USD365
2020-01-01 to 2020-12-31-2,699,236USD366

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2021-10-01 to 2021-12-31-667,844USD92
2021-07-01 to 2021-09-30-1,058,657USD92
2021-04-01 to 2021-06-30-553,701USD91
2021-01-01 to 2021-03-31-513,742USD90
2020-10-01 to 2020-12-31-1,711,154USD92
2020-07-01 to 2020-09-30535,885USD92
2020-04-01 to 2020-06-30-294,798USD91
2020-01-01 to 2020-03-31-241,816USD91

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2021-01-01 to 2021-12-31-3,079,512USD365
2020-01-01 to 2020-12-31-1,997,450USD366

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2021-01-01 to 2021-12-311,273,808USD365
2020-01-01 to 2020-12-31603,632USD366

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2021-01-01 to 2021-12-3132,065USD365
2020-01-01 to 2020-12-3138,119USD366

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2021-01-01 to 2021-12-311,038,816USD365
2020-01-01 to 2020-12-31409,368USD366

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2021-01-01 to 2021-12-3183,999USD365
2020-01-01 to 2020-12-31180,559USD366

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-987,353USD366

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-6,845USD366

Inspect the source

Entity
Evolutionary Genomics, Inc. / CIK 0000884363
Captured
SEC response SHA-256
a2b66772c1d0ab2271c82d2191d0de1fc92fc9df77b277aa7e747ea7abf31177

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000884363.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))